Search
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalhas made it a desirable therapeutic target in MF treatment. … of both primary and secondary MF in patients with platelet counts < 50 x 10<sup>9</sup>/L.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersAdefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedIt is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir. … of hepatitis B.
Categories: Heterocyclic Compounds, 2-Ring, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase InhibitorInternational brands: A Di Xian, A Gan DingSulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalin adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Synonyms: sulfur(6+) fluorideProducts: SONOVUE POWDER FOR DISPERSION FOR INJECTION 8 microlitres/mlLorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder.[A31634] It is a piperazinyl-triazole derivative.[T83]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesMetharbital
go.drugbank.com/drugs/DB00463ApprovedWithdrawnMetharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.
Categories: Heterocyclic Compounds, 1-RingEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigational[A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells … Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: DAXAS®Pyruvic acid
go.drugbank.com/drugs/DB00119ApprovedInvestigationalNutraceutical(From Stedman, 26th ed) … An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.
Synonyms: 2-Oxopropansäure, 2-OxopropionsäureIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid, BORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnMafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements
Synonyms: 4-Homosufanilamide, 4-(aminomethyl)benzenesulfonamide